A12 anti-PD-L1 CAR T cells

A12 anti-PD-L1 CAR T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy that utilizes a camelid-derived single-domain antibody fragment (VHH or nanobody), specifically the A12 clone, for antigen recognition. This therapy is designed to target Programmed Death-Ligand 1 (PD-L1), which is frequently overexpressed on tumor cells and within the immunosuppressive tumor microenvironment (TME). Unlike traditional CAR T cells that use single-chain variable fragments (scFvs), the VHH-based A12 CAR offers high stability and a modular design. The mechanism of action is twofold: the CAR T cells exert direct cytolytic activity against PD-L1-positive cells and simultaneously act as a competitive antagonist to block the PD-1/PD-L1 inhibitory axis, thereby relieving immune suppression. Preclinical studies in immunocompetent murine models of melanoma and colon adenocarcinoma have demonstrated that A12 CAR T cells can significantly inhibit tumor growth and improve survival, even in the absence of lymphodepletion.

Other names

A12 CAR T cellsA-12 CAR T cellsA 12 CAR T cellsanti-PD-L1 VHH-based CAR T cellsanti-PD-L-1 VHH-based CAR T cellsanti-PD-L 1 VHH-based CAR T cellsA12 anti-PD-L1 CAR-TA-12 anti-PD-L1 CAR-TA 12 anti-PD-L1 CAR-T